1-16 of 16
Bruce Ruggeri
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

PRT2527, a Novel Highly Selective Cyclin-Dependent Kinase 9 (CDK9) Inhibitor, Has Potent Anti-Leukemic Activity in Preclinical Primary Models of Human B-ALL, T-ALL, and CLL

Neha Bhagwat, Bruce Ruggeri, Yang Zhang, Yaron Mosesson, Clare Killick-Cole, Veena Jagannathan, Peggy Scherle
Journal: Blood
Blood (2022) 140 (Supplement 1): 505–506.
https://doi.org/10.1182/blood-2022-158998
Published: 2022
Journal Articles

Preclinical Activity of the Clinical Stage Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor PRT543 in Splicing Mutant Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

Leya Y Schwartz, Gaurav S Choudhary, Nandini Ramachandra, Srabani Sahu, Shanisha Gordon, Bruce Ruggeri, Diane Heiser, Peggy Scherle, Daniel Starczynowski, Amit Verma
Journal: Blood
Blood (2021) 138 (Supplement 1): 2597.
https://doi.org/10.1182/blood-2021-148494
Published: 2021
Journal Articles

Evaluating the Efficacy of PRMT5 Inhibitor C220 in Patient-Derived Xenograft Models of Pediatric Acute Myeloid Leukemia

Anilkumar Gopalakrishnapillai, Anne Kisielewski, Yang Zhang, Bruce Ruggeri, Peggy Scherle, E. Anders Kolb, Sonali P. Barwe
Journal: Blood
Blood (2021) 138 (Supplement 1): 1170.
https://doi.org/10.1182/blood-2021-151671
Published: 2021
Journal Articles

Patient-Derived Acute Myeloid Leukemia (AML) Ex Vivo platform for Evaluation of Novel Molecular Targeted Therapeutic Agents

Bhavna Verma, Nicolett Biel, Bruce Ruggeri, Amy Wesa
Journal: Blood
Blood (2019) 134 (Supplement_1): 5146.
https://doi.org/10.1182/blood-2019-126127
Published: 2019
Journal Articles

Itacitinib, a JAK1 Selective Inhibitor Preserves Graft-Versus-Leukemia (GVL), Enhances Survival and Is Highly Efficacious in a MHC-Mismatched Mouse Model of Acute GvHD

Ashish Juvekar, Bruce Ruggeri, Sindy Condon, Andrew Borkowski, Reid Huber, PhD, Paul Smith
Journal: Blood
Blood (2018) 132 (Supplement 1): 4522.
https://doi.org/10.1182/blood-2018-99-112144
Published: 2018
Journal Articles

Ruxolitinib, a JAK1/JAK2 Selective Inhibitor Is Highly Efficacious in Corticosteroid Untreated and Refractory MHC-Mismatched Mouse Model of Acute GvHD

Ashish Juvekar, Bruce Ruggeri, Sindy Condon, Andrew Borkowski, Reid Huber, PhD, Paul Smith
Journal: Blood
Blood (2018) 132 (Supplement 1): 4523.
https://doi.org/10.1182/blood-2018-99-112223
Published: 2018
Journal Articles

Redundant JAK, SRC and PI3 Kinase Signaling Pathways Regulate Cell Survival in Human Ph-like ALL Cell Lines and Primary Cells

Christian Hurtz, PhD, Sarah K Tasian, MD, Gerald Wertheim, MD, PhD, Bruce Ruggeri, Matthew C. Stubbs, Alexander E. Perl, MD, Martin Carroll, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 717.
https://doi.org/10.1182/blood.V130.Suppl_1.717.717
Published: 2017
Journal Articles

The Pan-PIM Inhibitor INCB053914 Displays Potent Synergy at Low Doses in Combination with Ruxolitinib in Pre-Clinical Models of MPNs

Lucia Mazzacurati, Que T. Lambert, Robert J. Collins, Holly K. Koblish, PhD, Bruce Ruggeri, Matthew C. Stubbs, Gary W. Reuther, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1661.
https://doi.org/10.1182/blood.V130.Suppl_1.1661.1661
Published: 2017
Journal Articles

LSD1 Inhibition Induces Fetal Hemoglobin Expression and Provides a Novel Therapeutic Approach to Sickle Cell Disease

Sang Hyun Lee, PhD, Maxim Soloviev, MDPhD, Yan Zhang, PhD, Valerie Roman, Gengjie Yang, Kevin Bowman, Krista Burke, Alexander Margulis, Sybil O'Connor, Yan-ou Yang, PhD, Liangxing Wu, PhD, Richard Wynn, PhD, Timothy Burn, PhD, Dana Shuey, PhD, Sharon Diamond, PhD, Wenqing Yao, PhD, Gregory Hollis, PhD, Swamy Yeleswaram, PhD, Alan Roberts, PhD, Reid Huber, PhD, Peggy Scherle, PhD, Bruce Ruggeri, PhD
Journal: Blood
Blood (2016) 128 (22): 2472.
https://doi.org/10.1182/blood.V128.22.2472.2472
Published: 2016
Journal Articles

The enzymatic activity of 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase is enhanced by NPM-ALK: new insights in ALK-mediated pathogenesis and the treatment of ALCL

Francesco E. Boccalatte, Claudia Voena, Chiara Riganti, Amalia Bosia, Lucia D'Amico, Ludovica Riera, Mangeng Cheng, Bruce Ruggeri, Ole N. Jensen, Valerie L. Goss, Kimberly Lee, Julie Nardone, John Rush, Roberto D. Polakiewicz, Michael J. Comb, Roberto Chiarle, Giorgio Inghirami
Journal: Blood
Blood (2009) 113 (12): 2776–2790.
https://doi.org/10.1182/blood-2008-06-161018
Published: 2009
Includes: Supplemental data
Journal Articles

NPM-ALK Mutants in Kinase Domain Exhibit Altered Kinase Activity and Various Sensitivity to ALK Inhibitors.

Lihui Lu, Arup Ghose, Matt Quail, Bruce Ruggeri, Mangeng Cheng
Journal: Blood
Blood (2008) 112 (11): 1603.
https://doi.org/10.1182/blood.V112.11.1603.1603
Published: 2008
Journal Articles

Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders

Elizabeth O. Hexner, Cynthia Serdikoff, Mahfuza Jan, Cezary R. Swider, Candy Robinson, Shi Yang, Thelma Angeles, Stephen G. Emerson, Martin Carroll, Bruce Ruggeri, Pawel Dobrzanski
Journal: Blood
Blood (2008) 111 (12): 5663–5671.
https://doi.org/10.1182/blood-2007-04-083402
Published: 2008
Includes: Supplemental data
Journal Articles

CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib

Roberto Piva, Bruce Ruggeri, Michael Williams, Giulia Costa, Ilaria Tamagno, Dario Ferrero, Valentina Giai, Marta Coscia, Silvia Peola, Massimo Massaia, Gabriella Pezzoni, Cecilia Allievi, Nicoletta Pescalli, Mara Cassin, Stefano di Giovine, Paola Nicoli, Paola de Feudis, Ivan Strepponi, Ilaria Roato, Riccardo Ferracini, Benedetta Bussolati, Giovanni Camussi, Susan Jones-Bolin, Kathryn Hunter, Hugh Zhao, Antonino Neri, Antonio Palumbo, Celia Berkers, Huib Ovaa, Alberto Bernareggi, Giorgio Inghirami
Journal: Blood
Blood (2008) 111 (5): 2765–2775.
https://doi.org/10.1182/blood-2007-07-100651
Published: 2008
Journal Articles

CEP-701 Is a JAK2 Inhibitor Which Attenuates JAK2/STAT5 Signaling Pathway and the Proliferation of Primary Cells from Patients with Myeloproliferative Disorders.

Pawel Dobrzanski, PhD, Elizabeth Hexner, MD, Cynthia Serdikoff, Mahfuza Jan, Cezary Swider, PhD, Candy Robinson, Shi Yang, PhD, Thelma Angeles, PhD, Stephen G. Emerson, MD,PhD, Martin Carroll, MD, Bruce Ruggeri, PhD
Journal: Blood
Blood (2006) 108 (11): 3594.
https://doi.org/10.1182/blood.V108.11.3594.3594
Published: 2006
Journal Articles

Identification and Characterization of an ALK Inhibitor That Attenuates the Proliferation and Survival of Anaplastic Large Cell Lymphoma-Derived Cell Lines and ALK Dependent Cell Lines.

Mangeng Cheng, Ph.D., Weihua Wan, Mark Albom, Linda Weinberg, Thelma Angeles, Ph.D., Matthew Quail, Lihui Lu, Ted Underiner, Ph.D., Robert Hudkins, Ph.D., Mark Ator, Ph.D., Bruce Ruggeri, Ph.D.
Journal: Blood
Blood (2004) 104 (11): 2485.
https://doi.org/10.1182/blood.V104.11.2485.2485
Published: 2004
Journal Articles

A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo

Mark Levis, Jeffrey Allebach, Kam-Fai Tse, Rui Zheng, Brenda R. Baldwin, B. Douglas Smith, Susan Jones-Bolin, Bruce Ruggeri, Craig Dionne, Donald Small
Journal: Blood
Blood (2002) 99 (11): 3885–3891.
https://doi.org/10.1182/blood.V99.11.3885
Published: 2002